Table 4.
Univariable and multivariable Cox regression for progression-free survival to first exposure CPI
| Variable | Univariable | Multivariable | ||
| HR (95% CI) | P value | HR (95% CI) | P value | |
| First CPI exposure | ||||
| Anti-PD-1 | 1 | 1 | ||
| Anti-PD-1/ipilimumab | 0.85 (0.61 to 1.19) | 0.35 | 0.77 (0.55 to 1.10) | 0.15 |
| Ipilimumab | 1.50 (1.15 to 1.97) | 0.0032 | 1.48 (1.09 to 1.99) | 0.01 |
| Stage of advanced disease | ||||
| Unresectable IIIB | 1 | 1 | ||
| Unresectable IIIC | 0.68 (0.29 to 1.59) | 0.37 | 0.74 (0.31 to 1.77) | 0.50 |
| Unresectable IIID | 0.81 (0.31 to 2.14) | 0.67 | 0.94 (0.35 to 2.52) | 0.91 |
| M1a | 1.08 (0.47 to 2.57) | 0.83 | 1.22 (0.51 to 2.87) | 0.66 |
| M1b | 0.90 (0.39 to 2.09) | 0.80 | 0.89 (0.38 to 2.09) | 0.79 |
| M1c | 0.87 (0.38 to 2.01) | 0.75 | 0.86 (0.37 to 1.99) | 0.72 |
| M1d | 2.81 (1.17 to 7.05) | 0.02 | 2.75 (1.08 to 6.99) | 0.03 |
| Primary acral melanoma site | ||||
| Subungual | 1 | |||
| Plantar | 0.76 (0.57 to 1.01) | 0.05 | – | – |
| Palmar | 0.69 (0.41 to 1.19) | 0.18 | – | – |
| Sex | ||||
| Female | 1 | |||
| Male | 1.04 (0.82 to 1.31) | 0.74 | – | – |
| Ethnicity | ||||
| Non-Caucasian | 1 | |||
| Caucasian | 0.98 (0.73 to 1.32) | 0.89 | – | – |
| LDH | ||||
| Normal (≤ULN) | 1 | |||
| Elevated (>ULN) | 1.26 (0.93 to 1.73) | 0.14 | – | – |
| ECOG | ||||
| 0 | 1 | 1 | ||
| ≥1 | 1.35 (1.04 to 1.74) | 0.02 | 1.28 (0.97 to 1.67) | 0.08 |
CPI, checkpoint inhibitor; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; PD-1, programmed cell death protein-1; ULN, upper limited of normal.